Assuntos
Portador Sadio/terapia , Erradicação de Doenças , Saúde Global , Vacinas contra Hepatite B/uso terapêutico , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/prevenção & controle , Administração Intravenosa , Carcinoma Hepatocelular/epidemiologia , Portador Sadio/epidemiologia , Portador Sadio/virologia , Usuários de Drogas , Custos de Cuidados de Saúde , Vacinas contra Hepatite B/economia , Hepatite C Crônica/transmissão , Humanos , Incidência , Neoplasias Hepáticas/epidemiologia , RiscoRESUMO
Hepatitis C virus (HCV) is 15 times more prevalent among persons in Spain's prisons than in the community. Recently, Spain initiated a pilot program, JAILFREE-C, to treat HCV in prisons using direct-acting antivirals (DAAs). Our aim was to identify a cost-effective strategy to scale-up HCV treatment in all prisons. Using a validated agent-based model, we simulated the HCV landscape in Spain's prisons considering disease transmission, screening, treatment, and prison-community dynamics. Costs and disease outcomes under status quo were compared with strategies to scale-up treatment in prisons considering prioritization (HCV fibrosis stage vs. HCV prevalence of prisons), treatment capacity (2,000/year vs. unlimited) and treatment initiation based on sentence lengths (>6 months vs. any). Scaling-up treatment by treating all incarcerated persons irrespective of their sentence length provided maximum health benefits-preventing 10,200 new cases of HCV, and 8,300 HCV-related deaths between 2019-2050; 90% deaths prevented would have occurred in the community. Compared with status quo, this strategy increased quality-adjusted life year (QALYs) by 69,700 and costs by 670 million, yielding an incremental cost-effectiveness ratio of 9,600/QALY. Scaling-up HCV treatment with DAAs for the entire Spanish prison population, irrespective of sentence length, is cost-effective and would reduce HCV burden.
Assuntos
Antivirais/economia , Análise Custo-Benefício , Hepacivirus/efeitos dos fármacos , Hepatite C Crônica/economia , Hepatite C Crônica/epidemiologia , Prisioneiros , Adulto , Antivirais/uso terapêutico , Feminino , Custos de Cuidados de Saúde/estatística & dados numéricos , Hepacivirus/crescimento & desenvolvimento , Hepacivirus/patogenicidade , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/transmissão , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Estatísticos , Prevalência , Prisões , Anos de Vida Ajustados por Qualidade de Vida , Espanha/epidemiologiaRESUMO
BACKGROUND: The revolution in hepatitis C virus (HCV) treatment through the development of direct-acting antivirals (DAAs) has generated international interest in the global elimination of the disease as a public health threat. In 2017, this led WHO to establish elimination targets for 2030. We evaluated the impact of public health interventions on the global HCV epidemic and investigated whether WHO's elimination targets could be met. METHODS: We developed a dynamic transmission model of the global HCV epidemic, calibrated to 190 countries, which incorporates data on demography, people who inject drugs (PWID), current coverage of treatment and prevention programmes, natural history of the disease, HCV prevalence, and HCV-attributable mortality. We estimated the worldwide impact of scaling up interventions that reduce risk of transmission, improve access to treatment, and increase screening for HCV infection by considering six scenarios: no change made to existing levels of diagnosis or treatment; sequentially adding the following interventions: blood safety and infection control, PWID harm reduction, offering of DAAs at diagnosis, and outreach screening to increase the number diagnosed; and a scenario in which DAAs are not introduced (ie, treatment is only with pegylated interferon and oral ribavirin) to investigate the effect of DAA use. We explored the effect of varying the coverage or impact of these interventions in sensitivity analyses and also assessed the impact on the global epidemic of removing certain key countries from the package of interventions. FINDINGS: By 2030, interventions that reduce risk of transmission in the non-PWID population by 80% and increase coverage of harm reduction services to 40% of PWID could avert 14·1 million (95% credible interval 13·0-15·2) new infections. Offering DAAs at time of diagnosis in all countries could prevent 640â000 deaths (620â000-670â000) from cirrhosis and liver cancer. A comprehensive package of prevention, screening, and treatment interventions could avert 15·1 million (13·8-16·1) new infections and 1·5 million (1·4-1·6) cirrhosis and liver cancer deaths, corresponding to an 81% (78-82) reduction in incidence and a 61% (60-62) reduction in mortality compared with 2015 baseline. This reaches the WHO HCV incidence reduction target of 80% but is just short of the mortality reduction target of 65%, which could be reached by 2032. Reducing global burden depends upon success of prevention interventions, implemention of outreach screening, and progress made in key high-burden countries including China, India, and Pakistan. INTERPRETATION: Further improvements in blood safety and infection control, expansion or creation of PWID harm reduction services, and extensive screening for HCV with concomitant treatment for all are necessary to reduce the burden of HCV. These findings should inform the ongoing global action to eliminate the HCV epidemic. FUNDING: Wellcome Trust.
Assuntos
Hepacivirus/efeitos dos fármacos , Hepatite C Crônica/tratamento farmacológico , Hepatite C/tratamento farmacológico , Modelos Teóricos , Antivirais/uso terapêutico , China/epidemiologia , Acessibilidade aos Serviços de Saúde , Hepatite C/epidemiologia , Hepatite C/prevenção & controle , Hepatite C/transmissão , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/prevenção & controle , Hepatite C Crônica/transmissão , Humanos , Incidência , Índia/epidemiologia , Programas de Rastreamento/métodos , Mortalidade , Paquistão/epidemiologia , Prevalência , Organização Mundial da Saúde/organização & administraçãoRESUMO
AIM: To evaluate the cost-effectiveness of needle and syringe programmes (NSPs) compared with no NSPs on hepatitis C virus (HCV) transmission in the United Kingdom. DESIGN: Cost-effectiveness analysis from a National Health Service (NHS)/health-provider perspective, utilizing a dynamic transmission model of HCV infection and disease progression, calibrated using city-specific surveillance and survey data, and primary data collection on NSP costs. The effectiveness of NSPs preventing HCV acquisition was based on empirical evidence. SETTING AND PARTICIPANTS: UK settings with different chronic HCV prevalence among people who inject drugs (PWID): Dundee (26%), Walsall (18%) and Bristol (45%) INTERVENTIONS: Current NSP provision is compared with a counterfactual scenario where NSPs are removed for 10 years and then returned to existing levels with effects collected for 40 years. MEASUREMENTS: HCV infections and cost per quality-adjusted life year (QALY) gained through NSPs over 50 years. FINDINGS: Compared with a willingness-to-pay threshold of £20 000 per QALY gained, NSPs were highly cost-effective over a time-horizon of 50 years and decreased the number of HCV incident infections. The mean incremental cost-effectiveness ratio was cost-saving in Dundee and Bristol, and £596 per QALY gained in Walsall, with 78, 46 and 40% of simulations being cost-saving in each city, respectively, with differences driven by coverage of NSP and HCV prevalence (lowest in Walsall). More than 90% of simulations were cost-effective at the willingness-to-pay threshold. Results were robust to sensitivity analyses, including varying the time-horizon, HCV treatment cost and numbers of HCV treatments per year. CONCLUSIONS: Needle and syringe programmes are a highly effective low-cost intervention to reduce hepatitis C virus transmission, and in some settings they are cost-saving. Needle and syringe programmes are likely to remain cost-effective irrespective of changes in hepatitis C virus treatment cost and scale-up.
Assuntos
Hepatite C Crônica/prevenção & controle , Programas de Troca de Agulhas/economia , Abuso de Substâncias por Via Intravenosa/terapia , Simulação por Computador , Análise Custo-Benefício , Hepatite C Crônica/economia , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/transmissão , Humanos , Programas de Troca de Agulhas/métodos , Anos de Vida Ajustados por Qualidade de Vida , Medicina Estatal/economia , Reino UnidoRESUMO
PURPOSE: Hepatitis C, a chronic disease with deadly consequences, is no longer predominantly a disease of older people. METHODS: A limited search was conducted of the relevant literature on 2 topics: (1) the impact of hepatitis C on infants exposed by vertical transmission; and (2) the impact of hepatitis C infection on infected children and adolescents. The findings were supplemented by the first-hand experience of the authors. FINDINGS: Young people, including women of childbearing age, infants, children, and adolescents, are being especially affected by hepatitis C infection secondary to the intravenous drug use and opioid epidemic. Unfortunately, estimates of disease in young populations are all misleading because universal screening has not been implemented. IMPLICATIONS: Lack of implementation of policies for screening and therapy on most affected populations will be responsible for perpetuation of this infection. In the era of highly effective therapy and a regimen that is approved by the US Food and Drug Administration for children, this outcome is unacceptable.
Assuntos
Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/transmissão , Transmissão Vertical de Doenças Infecciosas , Complicações Infecciosas na Gravidez/tratamento farmacológico , Adolescente , Criança , Análise Custo-Benefício , Feminino , Hepacivirus , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/epidemiologia , Humanos , Lactente , Gravidez , Complicações Infecciosas na Gravidez/diagnóstico , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Hepatitis C (HCV) is a global public health concern. There is a global prevalence of 15% among the world's prisoner population, suggesting the need for priority HCV treatment among this population group. New highly efficacious therapies with low side effects, known as directing-acting antivirals, became available under Australia's universal healthcare scheme on 1 March 2016. This creates an opportune time to trial treatment as prevention as an elimination strategy for HCV in prison settings. This paper examines whether policies in Australian jurisdictions support treatment scale-up to achieve elimination among this priority population. METHODS: A comprehensive search was conducted using Google and other web-based search functions to locate all publicly available policies in each Australian state and territory related to HCV health and HCV-related prison health. Ministers (corrections and health) were contacted from each jurisdiction to identify any additional policies. Inductive and deductive analyses were conducted for each jurisdiction, with documents being assessed against a set of four a priori criteria. Documents included in the analysis were current at 1 September 2017, or 18 months following treatment availability. RESULTS: A total of 18 documents were located, including both health (n = 12) and corrections/prison health (n = 6) documents relevant to HCV. Jurisdictions ranged in their commitments for delivering HCV harm reduction strategies and treatment availability within the prison setting. CONCLUSION: Few jurisdictions have updated or published HCV-related health or prisoner health policies following availability of directing-acting antivirals. Current policies do not provide effective support for implementing treatment scale-up that could be possible under universal access to HCV treatment among this priority population.
Assuntos
Política de Saúde , Hepatite C Crônica/prevenção & controle , Austrália/epidemiologia , Redução do Dano , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/transmissão , Humanos , Prisioneiros/estatística & dados numéricos , Prisões/estatística & dados numéricos , Recidiva , Fatores de Risco , Abuso de Substâncias por Via Intravenosa/epidemiologiaRESUMO
Direct-acting antivirals (DAAs) represent an opportunity to improve hepatitis C virus (HCV) care cascade. This combined with improved harm reduction interventions may lead to HCV elimination especially in people who inject drugs (PWID). We assessed the effectiveness/cost-effectiveness of improvements in harm reduction and chronic hepatitis C (CHC) care cascade in PWID in France. We used a dynamic model of HCV transmission and CHC natural history and evaluated the following: improved needle/syringe programmes-opioid substitution therapies, faster diagnosis/linkage to care, earlier treatment initiation, alone and in combination among active PWID (mean age = 36). Outcomes were as follows: life expectancy in discounted quality-adjusted life years (QALYs); direct lifetime discounted costs; incremental cost-effectiveness ratio (ICER); number of infections/reinfections. Under the current practice, life expectancy was 15.846 QALYs, for a mean lifetime cost of 20 762. Treatment initiation at F0 fibrosis stage alone was less effective and more costly than faster diagnosis/linkage to care combined with treatment initiation at F0, which increased life expectancy to 16.694 QALYs, decreased new infections by 37%, with a ICER = 5300/QALY. Combining these interventions with harm reduction improvements was the most effective scenario (life expectancy = 16.701 QALYs, 41% decrease in new infections) but was not cost-effective (ICER = 105 600/QALY); it became cost-effective with higher initial HCV incidence rates and lower harm reduction coverage than in our base-case scenario. This study illustrated the high effectiveness, and cost-effectiveness, of a faster diagnosis/linkage to care together with treatment from F0 with DAAs. This "Test and treat" strategy should play a central role both in improving the life expectancies of HCV-infected patients, and in reducing HCV transmission.
Assuntos
Antivirais/uso terapêutico , Redução do Dano , Hepatite C Crônica/prevenção & controle , Hepatite C/tratamento farmacológico , Abuso de Substâncias por Via Intravenosa/complicações , Antivirais/economia , Análise Custo-Benefício , Progressão da Doença , Transmissão de Doença Infecciosa/prevenção & controle , França/epidemiologia , Hepatite C/diagnóstico , Hepatite C/epidemiologia , Hepatite C/transmissão , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/transmissão , Humanos , Modelos Teóricos , Anos de Vida Ajustados por Qualidade de Vida , Abuso de Substâncias por Via Intravenosa/epidemiologiaAssuntos
Letramento em Saúde/métodos , Pessoal de Saúde/educação , Hepatite C Crônica/prevenção & controle , Transmissão de Doença Infecciosa do Profissional para o Paciente/prevenção & controle , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Adulto , Transfusão de Sangue/economia , Criança , Feminino , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/transmissão , Humanos , Incidência , Controle de Infecções/economia , Masculino , Paquistão/epidemiologia , Prevalência , Fatores Socioeconômicos , Esterilização/economia , Organização Mundial da SaúdeRESUMO
OBJECTIVES: To investigate the value of expanding screening and treatment for hepatitis C virus (HCV) infection in the United States. STUDY DESIGN: Discrete-time Markov model. METHODS: We modeled HCV progression and transmission to analyze the costs and benefits of investment in screening and treatment over a 20-year time horizon. Population-level parameters were estimated using National Health and Nutrition Examination Survey data and published literature. We considered 3 screening scenarios that vary in terms of clinical guidelines and physician awareness of guidelines. For each screening scenario, we modeled 3 approaches to treatment, varying the fibrosis stage of treatment initiation. Net social value was the key model outcome, calculated as the value of benefits from improved quality-adjusted survival and reduced transmission minus screening, treatment, and medical costs. RESULTS: Expanded screening policies generated the largest value to society. However, this value is constrained by the availability of treatment to diagnosed patients. Screening all individuals in the population generates $0.68 billion in social value if diagnosed patients are treated in fibrosis stages F3-F4 compared with $824 billion if all diagnosed patients in stages F0-F4 are treated. Moreover, increased screening generates cumulative net social value by year 8 to 9 under expanded treatment policies compared with 20 years if only patients in stages F3-F4 are treated. CONCLUSIONS: Although increasing screening for HCV may generate some value to society, only when paired with expanded access to treatment at earlier disease stages will it produce considerable value. Such a "test and treat" strategy is likely to entail higher short-term costs but also yield the greatest social benefits.
Assuntos
Antivirais/economia , Hepatite C Crônica/economia , Programas de Rastreamento/economia , Antivirais/uso terapêutico , Análise Custo-Benefício , Progressão da Doença , Custos de Medicamentos , Diagnóstico Precoce , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/transmissão , Humanos , Cadeias de Markov , Modelos Econômicos , Inquéritos Nutricionais/estatística & dados numéricos , Anos de Vida Ajustados por Qualidade de Vida , Valores Sociais , Estados UnidosRESUMO
OBJECTIVES: Hepatitis C virus (HCV) treatment incentives for private payers may be misaligned because payers must bear immediate costs and may not realize long-term benefits. However, these benefits may accrue to future payers, including Medicare. We examined how and to what extent private payers' current HCV treatment coverage decisions impact Medicare's and private payers' future costs. STUDY DESIGN: Discrete-time Markov model. METHODS: We modeled HCV disease progression and transmission to simulate the economic and social effects of different private-payer HCV treatment scenarios on Medicare. The model examined differences between a baseline scenario (current practice guidelines) and 2 alternative scenarios that expand treatment coverage. Spillover effects were measured as reduced HCV treatment costs and medical expenditures in Medicare. We calculated the spillover effects and net social value of each scenario (total value of quality-adjusted life-years accrued over time minus cumulative treatment and medical costs). RESULTS: With expanded HCV treatment coverage, private payers experience reduced medical expenditures in the 3-to-5-year time horizon; however, they still face higher treatment costs. Over a 20-year horizon, private payers experience overall savings of $10 billion to $14 billion after treatment costs. The expansion of coverage by private payers generates positive spillover benefits to Medicare of $0.3 billion to $0.7 billion over a 5-year horizon, and $4 billion to $11 billion over a 20-year horizon. CONCLUSIONS: When private payers increase HCV treatment coverage, they may achieve significant savings while inducing spillover benefits to Medicare. Future savings, however, may not motivate immediate treatment investments among private payers who experience high beneficiary turnover.
Assuntos
Hepatite C Crônica/economia , Cobertura do Seguro/economia , Seguro Saúde/economia , Antivirais/economia , Antivirais/uso terapêutico , Simulação por Computador , Análise Custo-Benefício , Progressão da Doença , Diagnóstico Precoce , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/transmissão , Humanos , Cobertura do Seguro/normas , Seguro Saúde/normas , Cadeias de Markov , Medicare/economia , Modelos Econômicos , Inquéritos Nutricionais/estatística & dados numéricos , Setor Privado/economia , Anos de Vida Ajustados por Qualidade de Vida , Fatores de Tempo , Estados Unidos/epidemiologiaAssuntos
Antivirais/economia , Apoio Financeiro , Hepatite C Crônica/economia , Prisões/economia , Padrão de Cuidado/economia , Antivirais/uso terapêutico , Canadá , Transmissão de Doença Infecciosa , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/transmissão , Humanos , Programas de Troca de Agulhas/legislação & jurisprudência , Abuso de Substâncias por Via Intravenosa , Tempo para o TratamentoRESUMO
BACKGROUND AND AIM: Reducing the burden of hepatitis C virus (HCV) related liver disease will require treating people who inject drugs (PWID), the group at most risk of infection and transmission. We determine the cost-effectiveness of treating PWID with interferon-free direct-acting antiviral therapy in Australia. METHODS: Using a deterministic model of HCV treatment and liver disease progression, including a fixed rate of re-infection, the expected healthcare costs and quality-adjusted life years (QALYs) of a cohort of newly HCV-infected PWID were calculated for: no treatment; treatment after initial infection ("early-treatment"); and treatment prior to developing compensated cirrhosis ("late-treatment"). Incremental cost-effectiveness ratios (ICERs) were used to compare scenarios. RESULTS: Late-treatment was cost-effective compared to no treatment, with a discounted average gain of 2.98 (95%confidence interval 2.88-5.22) QALYs per person for an additional cost of $15,132 ($11,246-18,922), giving an ICER of $5078 ($2847-5295) per QALY gained. Compared to late-treatment, early-treatment gained a further discounted average of 2.27 (0.58-4.80) QALYs per person for $38,794 ($34,789-41,367), giving an ICER of $17,090 ($2847-63,282), which was cost-effective in approximately 90% of Monte-Carlo uncertainty simulations. For every 100 newly HCV-infected PWID, there were an estimated 40 (39-56) eventual liver-related deaths without treatment, compared to 7 (6-11) and 8 (7-13) with early-treatment and late-treatment available respectively. CONCLUSIONS: Treating HCV-infected PWID with new therapies is cost-effective and could prevent a significant number of liver-related deaths. Although late-treatment was the most cost-effective option, the cost per QALY gained for early-treatment compared to late-treatment is likely to be below unofficial Australian willingness to pay thresholds.
Assuntos
Antivirais/administração & dosagem , Antivirais/economia , Análise Custo-Benefício , Custos de Cuidados de Saúde , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/economia , Abuso de Substâncias por Via Intravenosa , Adolescente , Adulto , Austrália , Criança , Estudos de Coortes , Progressão da Doença , Hepatite C Crônica/mortalidade , Hepatite C Crônica/transmissão , Humanos , Modelos Biológicos , Anos de Vida Ajustados por Qualidade de Vida , Recidiva , Adulto JovemRESUMO
Chronic hepatitis C virus (HCV) infection is a major public health burden in Europe, being one of the leading causes of chronic liver disease, liver cirrhosis, and hepatocellular carcinoma. Properties of the HCV disease burden are heterogeneous across the European continent, with differences in incidence, prevalence, diagnosis and treatment rates, transmission routes, and genotype distribution. Recent estimates expect an increase in HCV-related morbidity and mortality in most European countries until 2030 even when current treatment options are taken into account. The European perspective on hepatitis C virus infection is summarized herein.
Assuntos
Hepatite C Crônica , Antivirais/uso terapêutico , Terapia Combinada , Efeitos Psicossociais da Doença , Europa (Continente)/epidemiologia , Genótipo , Acessibilidade aos Serviços de Saúde , Hepacivirus/genética , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/terapia , Hepatite C Crônica/transmissão , Hepatite C Crônica/virologia , Humanos , Incidência , Transplante de Fígado , PrevalênciaRESUMO
Chronic hepatitis C virus (HCV) infection is highly prevalent and associated with a wide range of hepatic and extrahepatic complications. The treatment landscape for HCV infection has evolved to include regimens without interferon formulations and/or ribavirin. This change simplifies therapy, improves tolerability, and decreases therapy duration, while improving virologic response rates. This article, the first in a series of 3, will provide an overview of the hepatitis C disease state, identify populations at risk for HCV, describe testing recommendations for the diagnosis of HCV infection, and distinguish new and emerging HCV therapies.
Assuntos
Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Ensaios Clínicos como Assunto , Infecções por HIV/tratamento farmacológico , Hepacivirus , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/transmissão , Humanos , Programas de Assistência Gerenciada , Medidas de Resultados Relatados pelo PacienteRESUMO
Hepatitis C infection is the most common blood-borne infection in the United States with an estimated 2.7 million individuals suffering from chronic infection. Of those who are infected with Hepatitis C virus, 75-85% develop chronic infection. Without treatment for chronic infection, individuals can develop liver diseases, such as cirrhosis and hepatocellular carcinoma, during many years of asymptomatic infection. To examine the burden of Hepatitis C virus infection in the state, the Arkansas Department of Health created an epidemiologic profile based on data collected in 2013 from several data sources, including the department's Hepatitis C surveillance program. In order to make more Arkansans aware of their infection, the local health units in all 75 counties of the state recently began screening individuals at risk for the disease, including persons born during the years 1945-1965. Despite recent advances in treatment efficacy, identifying infected individuals and connecting patients to affordable HCV treatment and care remain priorities.
Assuntos
Hepatite C Crônica/epidemiologia , Adolescente , Adulto , Idoso , Antivirais/economia , Antivirais/uso terapêutico , Arkansas , Estudos Transversais , Custos de Medicamentos , Feminino , Anticorpos Anti-Hepatite C/sangue , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/transmissão , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Ribavirina/economia , Ribavirina/uso terapêutico , Fatores de Risco , Sofosbuvir , Uridina Monofosfato/análogos & derivados , Uridina Monofosfato/economia , Uridina Monofosfato/uso terapêutico , Adulto JovemRESUMO
With the advent of all oral direct-acting antiviral drugs with a broad range of genotypic activity and a low incidence of side effects, we are entering an exciting new era in the therapeutics of hepatitis C virus (HCV). However, it is not yet clear who will benefit from these innovations: Will the advantages be limited to HCV patients in industrialized nations or could the whole community of HCV-infected individuals be given access to treatment? As the majority of people infected with HCV live in resource-limited settings it is important to overcome the barriers that restrict access to treatment in these areas. Drug costs, public and professional education, simplified diagnostics, and political imperative all need to be addressed before the majority of HCV-infected individuals can benefit from the new generation of HCV antivirals.
Assuntos
Antivirais/uso terapêutico , Países em Desenvolvimento , Saúde Global , Recursos em Saúde , Acessibilidade aos Serviços de Saúde , Disparidades em Assistência à Saúde , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/prevenção & controle , Antivirais/economia , Antivirais/provisão & distribuição , Países em Desenvolvimento/economia , Custos de Medicamentos , Saúde Global/economia , Saúde Global/legislação & jurisprudência , Política de Saúde , Recursos em Saúde/economia , Recursos em Saúde/legislação & jurisprudência , Recursos em Saúde/provisão & distribuição , Acessibilidade aos Serviços de Saúde/economia , Acessibilidade aos Serviços de Saúde/legislação & jurisprudência , Disparidades em Assistência à Saúde/economia , Disparidades em Assistência à Saúde/legislação & jurisprudência , Hepatite C Crônica/economia , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/transmissão , Humanos , Prevalência , Resultado do TratamentoAssuntos
Sorodiagnóstico da AIDS/métodos , Controle de Doenças Transmissíveis , Infecções por HIV , Conhecimentos, Atitudes e Prática em Saúde , Hepatite C Crônica , Programas de Rastreamento , Prisioneiros , Saliva/virologia , Controle de Doenças Transmissíveis/economia , Controle de Doenças Transmissíveis/métodos , Países em Desenvolvimento , Gana/epidemiologia , Anticorpos Anti-HIV/análise , Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , Infecções por HIV/transmissão , Anticorpos Anti-Hepatite C/análise , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/prevenção & controle , Hepatite C Crônica/transmissão , Humanos , Masculino , Programas de Rastreamento/métodos , Prevalência , Prisioneiros/psicologia , Prisões/economia , Saliva/imunologia , Estereotipagem , Inquéritos e QuestionáriosAssuntos
Hepatite C Crônica/transmissão , Transmissão de Doença Infecciosa do Paciente para o Profissional , Ferimentos Penetrantes Produzidos por Agulha/complicações , Exposição Ocupacional , Prurigo/etiologia , Adulto , Feminino , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/etiologia , Humanos , Seguro de Acidentes , Pensões , Prurigo/diagnóstico , Prurigo/tratamento farmacológico , Fatores de RiscoRESUMO
BACKGROUND & AIMS: Hepatitis C virus (HCV) screening can provide opportunities to reduce disease progression through counseling against alcohol use, but empirical data on this issue are sparse. We determined the efficacy of a behavioral intervention in reducing alcohol use among young, HCV-infected injection drug users (IDUs) (n=355) and assessed whether changes in liver enzymes were associated with changes in alcohol consumption. METHODS: Both the intervention and attention-control groups were counseled to avoid alcohol use, but the intervention group received enhanced counseling. Logistic regression, ANOVA, and continuous time Markov models were used to identify factors associated with alcohol use, changes in mean ALT and AST levels, and change in alcohol use post-intervention. RESULTS: Six months post-intervention, alcohol abstinence increased 22.7% in both groups, with no difference by intervention arm. Transition from alcohol use to abstinence was associated with a decrease in liver enzymes, with a marginally greater decrease in the intervention group (p=0.05 for ALT; p=0.06 for AST). In multivariate Markov models, those who used marijuana transitioned from alcohol abstinence to consumption more rapidly than non-users (RR=3.11); those who were homeless transitioned more slowly to alcohol abstinence (RR=0.47); and those who had ever received a clinical diagnosis of liver disease transitioned more rapidly to abstinence (RR=1.88). CONCLUSIONS: Although, behavioral counseling to reduce alcohol consumption among HCV-infected IDUs had a modest effect, reductions in alcohol consumption were associated with marked improvements in liver function. Interventions to reduce alcohol use among HCV-infected IDUs may benefit from being integrated into clinical care and monitoring of HCV infection.